TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00519012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline to Paroxetine
Description: For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine to Sertraline
Description: Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
Study: NCT03191487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual pathways
Description: In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
Study: NCT01454206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT
Description: Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use.
Study: NCT01944631

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray saline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iota-Carrageenan
Description: Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
Study: NCT00726206

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram, recording the movements
Description: Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
Study: NCT01708330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: odorless, colorless gel will be used as a placebo
Study: NCT02668523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
Study: NCT01698684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose 15 minutes before attempting intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Description: One dose 15 minutes before attempting intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Description: One dose 15 minutes before attempting intercourse
Study: NCT02539810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal artery Angioplasty plus stenting.
Description: renal artery stenting
Study: NCT02155218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gadolinium contrast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gadolinium contrast
Study: NCT02653001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sample collection
Description: Collection of complete stool sample
Study: NCT02539810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive, statin and antiplatelet medication.
Description: Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti hypertensive, statin and antiplatelet medication.
Description: Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
Study: NCT02184611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide
Description: Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
Study: NCT03530930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comarum Palustre
Description: Comarum Palustre tablets 500 mg BID, 1 month
Study: NCT02940366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg orally daily
Description: Pitavastatin 4 mg orally daily for 24months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20 mg orally daily
Description: Atorvastatin 20 mg orally daily for 24months
Study: NCT04375748

Intervention type: DIAGNOSTIC_TEST
Intervention: Performing routine care (clinical and paraclinical tests)
Description: ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Examinations for the research:
Description: Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)
Study: NCT03509649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine
Study: NCT01666951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro tablets
Description: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Tacrolimus
Study: NCT02672787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-based behavioral intervention
Description: Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED usual care plus education
Description: Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
Study: NCT04455789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine lung protective, conventional mechanical ventilation
Description: routine lung protective, conventional mechanical ventilation with stabil PEEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine lung protective, conventional mechanical ventilation
Description: routine lung protective, conventional mechanical ventilation with stabil PEEP
Study: NCT01808950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - A
Description: single 60mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - B
Description: single 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - C
Description: shave biopsy of BCC followed by single 100mg dose
Study: NCT05189808

Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation
Description: Ultrasound guided radiofrequency ablation (non-experimental)
Study: NCT00922285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: 6 weekly 60 minute sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Evaluated at baseline, week 1 and week 6 of art therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Evaluated at baseline, week 1 and week 6 of art therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress management therapy
Description: 6 weekly 60 minute sessions
Study: NCT00743769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymosin beta 4
Description: Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
Study: NCT02207010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
Study: NCT03491176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04466748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium enteric-coated tablet
Description: Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
Study: NCT02823951

Intervention type: DRUG
Intervention: Rebif

Intervention type: DRUG
Intervention: Rebif
Study: NCT02404740

Intervention type: DEVICE
Intervention: Pulse oximetry
Description: Pulse oximetry
Study: NCT02823951

Intervention type: DRUG
Intervention: Rebif

Intervention type: DRUG
Intervention: Rebif

Intervention type: DRUG
Intervention: Rebif

Intervention type: DRUG
Intervention: Tecfidera
Study: NCT01564134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
Study: NCT02404740

Intervention type: DEVICE
Intervention: Pulse oximetry
Description: Pulse oximetry

Intervention type: DEVICE
Intervention: Pulse oximetry
Description: Pulse oximetry
Study: NCT01004770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-145 (AN113111) Injection
Description: 40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque (iodixanol) Injection
Description: An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
Study: NCT02003495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV-ACYW135 Vaccine Group
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPV-ACYW135 Vaccine Group
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPV-A Vaccine Group
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MCV-AC Vaccine Group
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hib Vaccine Group
Description: 0.5ml, intramuscular
Study: NCT00987987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: regulatory T cells depletion
Study: NCT02424981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training
Description: Inspiratory muscle training
Study: NCT03404661

Intervention type: DRUG
Intervention: Synthetic Human Secretin
Description: Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.

Intervention type: DRUG
Intervention: Synthetic Human Secretin
Description: Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.

Intervention type: DRUG
Intervention: Synthetic Human Secretin
Description: Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
Study: NCT00729235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio CRT 6750
Description: Slow VT zone programmed as a Monitoring zone (Monitoring arm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio CRT 6750
Description: Slow VT zone programmed with ATP therapies (therapy arm).
Study: NCT03971942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral ABMT
Description: In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive ABMT
Description: In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
Study: NCT02823951

Intervention type: DRUG
Intervention: Tecfidera

Intervention type: DRUG
Intervention: Tecfidera

Intervention type: DRUG
Intervention: Tecfidera

Intervention type: DRUG
Intervention: Tecfidera
Study: NCT04474002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4L Klean Prep®
Description: Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1L Klean prep® and 2 sachets Picoprep®
Description: Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
Study: NCT02203747

Intervention type: OTHER
Intervention: Administration of patient self-assessment

Intervention type: OTHER
Intervention: Administration of patient self-assessment
Study: NCT01938976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge
Description: Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge
Description: Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
Study: NCT04616417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Investigational Oocyte Cryopreservation
Description: Transvaginal oocyte retrieval under ultrasound guidance
Study: NCT03058510

Intervention type: PROCEDURE
Intervention: Frequency domain optical coherence tomography
Description: OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
Study: NCT03333525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
Study: NCT02027779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg
Study: NCT04570566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal alveolar ridge augmentation
Description: evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal alveolar ridge augmentation
Description: evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
Study: NCT03646799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: test drug
Study: NCT01431755

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane SubQ
Description: Treatment with up to 2 ml of the product

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane SubQ Lidocaine
Description: Treatment with up to 2 ml of the product